newsfilter
← Latest News
Business Wire·

Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

  • Viridian Therapeutics (NASDAQ: VRDN) will report third quarter 2026 financial results before the market opens on Wednesday, November 4, 2026.
  • Management will host a live conference call on November 4, 2026 at 8:00 a.m. ET to discuss financial results & provide a business update.
  • The conference call webcast will be available via the "Events & Presentations" page in the Investors section of the Viridian Therapeutics website, with an archived version available following the live event.
  • The company is focused on developing medicines for autoimmune & rare diseases, utilizing expertise in antibody discovery & protein engineering.
  • Viridian has the FDA-approved drug Lumvoa™ (a full IGF-1R antagonist) for thyroid eye disease (TED) & is advancing elegrobart, a late-stage subcutaneous therapy for TED.
  • Viridian is headquartered in Waltham, Massachusetts.